Terns Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Merle - UBS Investment Bank - Analyst : I know we always guess around which we should focus more on the CML or obesity. I think we'll start with CML, just given the data is coming up. But I do think it's interesting that you're about 2 very different programs where we've seen some interesting clinic data. So starting with CML, maybe just high level, where do you see the role for another Allosteric inhibitor again sort of the use of Scemblix to date?

Question: Eliana Merle - UBS Investment Bank - Analyst : Great. And one of the questions that I get most from investors around your CML program is just what the unmet need is still in CML, particularly, I think it Scemblix as well as many generics?

Question: Eliana Merle - UBS Investment Bank - Analyst : Okay. Great. Makes sense. And so you're guiding for initial data from your Phase I in December. First, can you go over the trial design and how the inclusion criteria inform the potential opportunity across different lines?

Question: Eliana Merle - UBS Investment Bank - Analyst : Great. And in terms of specifics around number of patients and follow-up time, what should we be expecting from this data set in December?

Question: Eliana Merle - UBS Investment Bank - Analyst : And sorry, how much follow-up do these patients have?

Question: Eliana Merle - UBS Investment Bank - Analyst : And you alluded to it, but you did host a webinar that helped us understand how to evaluate early data in CML. What should we be looking for at this update? What is good data here and what you're looking to see?

Question: Eliana Merle - UBS Investment Bank - Analyst : Makes sense. And I guess just looking forward, so if we do see this reduction and sort of deepening of response in these patients, what are the next steps for the program?

Question: Eliana Merle - UBS Investment Bank - Analyst :

Question: Eliana Merle - UBS Investment Bank - Analyst : Yes. Any of the standard of care.

Question: Eliana Merle - UBS Investment Bank - Analyst : What are the most common causes of switching in the real world between sort of lack of response versus tolerability, safety, DDIs? And then I mean the reason I'm asking that is also in part in thinking about the patients that we'll be seeing data from in December?

Question: Eliana Merle - UBS Investment Bank - Analyst : Great. Makes sense. And maybe just last one and on to CML and feel free to ignore this but the latest commentary on when we might see more from Hansoh? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 13, 2024 / 4:45PM, TERN.OQ - Terns Pharmaceuticals Inc at UBS Global Healthcare Conference

Question: Eliana Merle - UBS Investment Bank - Analyst : With that, maybe we'll pivot to the obesity program and Jas, I'll pass it to you. Unidentified Participant Absolutely. So switching over to obesity, I guess let's just start with the data. So you recently reported Phase I data in the third quarter. So can you kind of just highlight what you saw for us? And are there any particular aspects of the data that you think deserve more focus or important?